35 results about "Collagen-induced arthritis" patented technology

The invention provides application of general inula helenium sesquiterpene lactone in preparation of a medicine for treating rheumatoid arthritis. The general inula helenium sesquiterpene lactone contains alantolactone and isoalantolactone; and the sum of the contents of the alantolactone and the isoalantolactone accounts for 60 to 90%. The results of animal pharmacodynamic tests show that the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can inhibit the clinical onset of CIA (Collagen-induced Arthritis), obviously inhibit the morbidity of CIA, obviously reduce the level of IFN(Interferon)-gamma, and remarkably inhibit the generation of IL(Interleukin)-17. Therefore, the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can be used for preparing the medicine for treating rheumatoid arthritis. The medicine is composed of the general inula helenium sesquiterpene lactone serving as an active ingredient and a pharmaceutic adjuvant and can be in form of a troche, a capsule, a soft capsule, a dropping pill, granules, an injection, a powder-injection or an aerosol and the like. The medicine provided by the invention is a new medicine for treating rheumatoid arthritis, which has remarkable curative effect and little side reaction; the raw materials are conveniently obtained, the preparation method is simple, and the medicine has relatively high clinical application value.

The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p161nk4a and p21Cip1 in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or the expression of inflammatory cytokines in synovial tissues targeting the p21Clip1 protein. Rheumatoid arthritis and other disorders associated with inflammation of the synovial tissue can be prevented or treated by promoting expression or function of p21Cip1 protein.

The present invention discloses a novel carbazole amide derivative or its salt represented by the general formula I with RORγt activity regulating effect and a preparation method thereof, and also discloses the use of the carbazole amide derivative or its salt in preparing therapeutic Use in medicine for diseases associated with RORγt. Experimental results show that the carbazole amide derivatives of the present invention or their salts can effectively regulate the activity of RORγt protein receptors, thereby regulating the differentiation of Th17 cells and the production of IL-17, and further serve as therapeutic drugs for the treatment of related diseases mediated by RORγt , especially for the treatment of multiple sclerosis, rheumatoid arthritis, collagen-induced arthritis, psoriasis, inflammatory bowel disease, encephalomyelitis, clonal disease, asthma and various cancers and other related diseases.

The invention belongs to the technical field of chemical medicines, and relates to a bridge ring piperazine derivative or salt thereof, a preparing method of the derivative and application of the bridge ring piperazine derivative or salt thereof in preparing medicines for treating ROR gamma t related diseases. Through experiments, the result shows that the bridge ring piperazine derivative can effectively restrain ROR gamma t protein receptors, adjust the differentiation of Th17 cells and restrain the generation of IL-17, can further be used as the treatment medicines for treating the ROR gamma t mediated inflammation related diseases and is particularly suitable for treating the inflammation related diseases such as disseminated sclerosis, rheumatoid arthritis, collagen induced arthritis,psoriasis, inflammatory bowel disease, encephalomyelitis, cloning diseases, asthma and cancers. The chemical formula can be seen in the description.

The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.

The invention discloses a total lignan extract of stalkedfruit pricklyash bark, which is characterized in that the content of total lignan is above 30%. The total lignan extract of stalkedfruit pricklyash bark is extracted and refined from the traditional Chinese medicine stalkedfruit pricklyash bark. Proven by pharmacodynamical and toxicological tests, the total lignan extract of stalkedfruit pricklyash bark can obviously improve the collagen induced arthritis of rats, and simultaneously has better analgesis and anti-inflammation effects with small toxic side effects. The invention also discloses a medical application of the total lignan extract of stalkedfruit pricklyash bark.

The invention provides an application of a traditional Chinese medicine huanglian jiedu decoction (comprising the Chinese medicine components of 9g of coptis chinensis, 6g of scutellaria baicalensis, 6g of golden cypress and 9g of gardenia) in preparing a medicament for preventing and treating rheumatoid arthritis. When being used for animal pharmacodynamic test, the huanglian jiedu decoction is proved to have the functions of restraining the clinical pothogenesy of CIA (Collagen-Induced Arthritis), obviously restraining the severity and the morbidity of the CIA and having obvious protection function to the CIA. The huanglian jiedu decoction can reduce the contents of TNF-alpha, IL-17 and IFN-gamma in splenocyte supernatant and restrain the secretion of proinflammatory cytokine, i.e. TNF-alpha, IFN-gamma and IL-17, thereby playing a protecting role for the CIA disease. The invention provides a new traditional Chinese medicine for clinically treating rheumatoid arthritis, which can overcome the toxic and side effects of pharmaceutical chemicals, thereby bringing confidence for treating and achieving higher clinical application value.